Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.00 EUR
Change Today 0.00 / 0.00%
Volume 0.0
ALCER On Other Exchanges
EN Paris
As of 11:50 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

cerep (ALCER) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEREP (ALCER)

Related News

No related news articles were found.

cerep (ALCER) Related Businessweek News

No Related Businessweek News Found

cerep (ALCER) Details

Eurofins Cerep SA provides in vitro pharmacology, in vitro ADME-Tox, and in vivo PK services to pharmaceutical and biotechnology companies worldwide. The company offers various research services, including compound management, high-throughput screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK; and custom research services comprising assay development, profile design, and data interpretation, as well as scientist-to-scientist communications. Its platforms cover a range of target classes, including ADME-Tox related targets, GPCRs, various enzymes, transporters, nuclear receptors, and ion channels; and employing methods and assay types, such as radioligand binding assays, calcium mobilization and cAMP measurement using TR-FRET, transporter/uptake assays, and bioluminescent and other fluorescent-based assays. Eurofins Cerep SA also provides BioPrint profiles and services, a homogenous pharmacology and ADME database comprising data sets, such as chemical descriptors, compound descriptors, and in vivo effects of drugs for use in drug discovery applications. The company was formerly known as Cerep SA and changed its name to Eurofins Cerep SA in June 2014. The company was founded in 1989 and is headquartered in Celle l’Evescault, France.

153 Employees
Last Reported Date: 05/28/15
Founded in 1989

cerep (ALCER) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cerep (ALCER) Key Developments

Eurofins Cerep SA to Report Fiscal Year 2014 Final Results on Apr 02, 2015

Eurofins Cerep SA announced that they will report fiscal year 2014 final results on Apr 02, 2015

Eurofins Cerep SA, Annual General Meeting, Jun 10, 2015

Eurofins Cerep SA, Annual General Meeting, Jun 10, 2015.

Eurofins Cerep SA to Report First Half, 2014 Results on Oct 28, 2014

Eurofins Cerep SA announced that they will report first half, 2014 results on Oct 28, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCER:FP €2.00 EUR 0.00

ALCER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALCER.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALCER Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEREP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at